Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. reported first‑quarter 2026 revenue of $374.8 million, up 15.6% from $324.1 million a year earlier, driven by growth in both thrombectomy and embolization/access products. Thrombectomy revenue reached $253.9 million, while embolization and access products generated $120.8 million.
Gross margin improved to 67.6% from 66.6%, but higher operating expenses, including acquisition‑related costs, reduced net income to $32.6 million from $39.2 million, with diluted EPS declining to $0.82 from $1.00. Operating cash flow strengthened to $87.0 million, supporting cash and cash equivalents of $241.3 million and marketable investments of $374.4 million.
The company entered into a definitive agreement to be acquired by Boston Scientific at $374 per Penumbra share, valuing the transaction at approximately $14.5 billion, with consideration mix targeted at roughly 73% cash and 27% Boston Scientific stock, subject to shareholder and regulatory approvals.
Penumbra, Inc. reported first quarter 2026 revenue of $374.8 million, up 15.6% from the first quarter of 2025, driven by growth in both thrombectomy and embolization businesses. Global thrombectomy revenue was $253.9 million, up 12.1%, while embolization and access revenue reached $120.8 million, up 23.8%.
Gross profit margin improved to 67.6%, but net income declined to $32.6 million from $39.2 million, reflecting higher operating expenses of $215.2 million, including $9.4 million of acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation. Diluted earnings per share were $0.82 versus $1.00 a year earlier.
Cash and cash equivalents were $241.3 million and marketable investments were $374.4 million as of March 31, 2026, supporting a total asset base of $1.90 billion. Given the pending acquisition by Boston Scientific, Penumbra is not providing full-year 2026 financial guidance and is not hosting a conference call for this quarter.
Penumbra Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 1,990,629 shares of common stock, representing 5.07% of the class. The filing shows sole power to dispose over 1,990,629 shares and sole voting power for 296,141 shares.
The filing lists affiliated Vanguard entities in the beneficial‑ownership statement and is signed by Ashley Grim as Head of Global Fund Administration on 04/30/2026.
Penumbra, Inc. is holding its 2026 annual stockholder meeting on June 18, 2026 to elect three Class II directors for one-year terms, ratify PricewaterhouseCoopers LLP as auditor for 2026, and approve on an advisory basis executive compensation.
The proxy also describes an Agreement and Plan of Merger under which Boston Scientific Corporation will acquire Penumbra in a transaction reflecting an enterprise value of approximately $14.5 billion. Each Penumbra share is valued at $374, with stockholders able to elect either $374 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to proration so that about 73% of total consideration is in cash and 27% in Boston Scientific stock. The merger requires separate stockholder approval at a special meeting and no merger-related action will be taken at this annual meeting.
Penumbra, Inc. sent letters urging stockholders to vote FOR the proposed merger with Boston Scientific and reminding recipients that failing to vote is treated the same as a vote against the Merger. The company notes the Proxy Statement/Prospectus on Form S-4 was declared effective on April 1, 2026 and that a Special Meeting of stockholders is scheduled for May 6, 2026. The letters instruct holders to vote by Internet, telephone, or by returning a proxy card, and identify Company and Parent sources for free copies of SEC filings. The communication includes standard forward-looking statements and a list of material risks described in the Proxy Statement/Prospectus.
Boston Scientific Corporation discussed Q1 2026 results and reiterated that its announced acquisition of Penumbra is expected to close in the second half of 2026, subject to the Penumbra shareholder vote on May 6th/7th and receipt of remaining regulatory clearances. The company said guidance excludes the Penumbra transaction and noted a recent tuck-in acquisition of Valencia Technologies.
The call emphasized growth in Interventional Oncology, continued prioritization of strategic tuck-in M&A and share repurchases, and that all revenue references on the call were organic and exclude certain recent acquisitions or divestitures.
The Company Penumbra, Inc. is soliciting votes in support of the proposed merger with Boston Scientific Corporation. The Board unanimously recommends shareholders vote FOR the Merger at a Special Meeting to be held on May 6, 2026. A Form S-4 proxy statement/prospectus was declared effective on April 1, 2026.
Stockholders are urged to read the Proxy Statement/Prospectus and may obtain free copies from the SEC or the companies' investor websites.
Penumbra Inc director Harpreet Grewal reported an open-market sale of 100 shares of common stock at $328.22 per share on April 2, 2026. After this transaction, Grewal directly holds 8,719 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, and a portion of the remaining shares is subject to vesting.
Penumbra, Inc. submitted a Rule 144 notice listing specific Common Stock transactions. The excerpt shows a 100-share lot linked to Fidelity Brokerage Services LLC with a numeric entry $32,822.00 and a separate entry showing 186 shares associated with Grewal Harpreet on 01/06/2026 with $58,151.04. Dates visible include 04/02/2026.